September 11th 2024
Push to identify biomarkers for earlier diagnosis, new therapeutic targets.
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Going to AAO? Join Us for Free CME In-Person or Virtually
October 18-19, 2024
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data
View More
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)
View More
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
New antibiotic seen as more effective in fighting bacteria
April 1st 2002San Francisco-Levofloxacin (Quixin, Santen)-the new kid in the fluoroquinolone family-is less likely to encounter resistant strains of bacteria than the two older members of that antibiotic family, ofloxacin (Ocuflox, Allergan) and ciprofloxacin (Ciloxan, Alcon), according to David Hwang, MD.
Read More
Single-piece lens may produce less striae
February 15th 2002Philadelphia-A case-control study-in which each patient served as his or her own control-found that a single-piece lens may be less likely to cause vision-troubling capsular striae than a multipiece lens, said Richard Tipperman, MD.
Read More
Less demanding famciclovir regimen compares with acyclovir
February 15th 2002Galveston, TX-Three-times-a-day treatment with famciclovir (Famvir, Novartis) was as effective against ophthalmic herpes zoster as five-times-a-day acyclovir (Zovirax, Glaxo Wellcome) in a major international trial, said Stephen K. Tyring, MD, PhD.
Read More
Retinal Prosthesis May do Work of Photoreceptor Cells
November 15th 2001Houston-An artificial retina could be the answer for an estimated 1 million Americans with retinal blindness by conditions such as retinitis pigmentosa and age-related macular degeneration, said Alex Ignatiev, PhD, professor of physics, chemistry, and electrical and computer engineering at the University of Houston.
Read More
Radiation may have potential to treat subfoveal CNV
September 17th 1Augusta, GA-Despite negative results in an early trial, effortsare continuing to determine whether external-beam irradiation can slow visionloss caused by subfoveal choroidal neovascularization (CNV) in age-relatedmacular degeneration (AMD), said Dennis M. Marcus, MD.
Read More